PPT-Advances and Challenges in HIV Antiretroviral Therapy

Camille Angle Meagan Bardan Hanna Schimjawicz and Sean Tabarah PHM142 Fall 2018 Instructor Ms Maya Latif Coordinator Dr J Henderson HIV Attachment and Penetration Wilen C B Tilton J C amp Doms R W D 2012 HIV Cell binding and entry . Targeted Cancer Therapies. Dr . Ongóndi. .M. KNH-Dept. Internal Medicine. Hemato. -Oncology. Objectives. Traditional chemotherapy. Targeted chemotherapy. Country status. Challenge !!!. Administer sufficiently high dose of . Brian R. Wood, MD. Assistant Professor of Medicine, University of Washington. Medical Director, NW AETC ECHO. Last Updated. : April 16, 2015. Source: . HHS . Antiretroviral Therapy Guidelines. . AIDS Info (www.aidsinfo.nih.gov). Simi Padival, MD. November 3, 2016. Objectives. Learn about the importance of assessing adherence to antiretroviral therapy (ART). Learn about the components of assessing for ART adherence. Discuss frequency of monitoring while on ART. Module 10:. Pharmacovigilance. Background – definitions. Timeline of pharmacovigilance for a drug from development (pre-market) to post-marketing use. Burden of adverse drug reactions in children. Number of pharmacoepidemiological safety studies in children (Osokogu et al, 2016). This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. implementation of Dolutegravir. Meireles MV. , Pascom ARP, Perini F, Rick F, Benzaken A. . Ministry of Health of Brazil, Department of STI, AIDS and Viral Hepatitis. Acknowledgements. No. . conflicts of interest. ACTIVITY CODE . TD342. Antiretroviral Medications: . What . you need to know. Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP. Associate Professor, Department of Pharmacy Practice. Joseph J. Eron, Jr, MD Professor of Medicine and Epidemiology The University of North Carolina at Chapel Hill Chapel Hill, North Carolina Future Directions: Investigational Approaches to Antiretroviral Therapy . Trikudanathan. , MD, MRCP, . MMSc. Division of Endocrinology, Metabolism and Nutrition. University of Washington Medical Center. Presentation prepared by: . S. . Trikudanathan. Presenter: S. . Trikudanathan. The University of North Carolina at Chapel Hill. Chapel Hill, North Carolina. Future Directions: Investigational Approaches to Antiretroviral Therapy. Washington, DC: . August . 24, . 2016. . Future Directions: . A5173 Study. Intensive . Enfuvirtide. -containing Antiretroviral Therapy . A5173: . Study Design. Source: Gandhi RT, et al. . J . Infect. . Dis. . . 2010;201(2. ):293-6.. Enfuvirtide. +. TDF + (FTC or 3TC) +. therapy. . on. . the. CD4/CD8 ratio and CD8 . cell. . counts. in . CoRIS. : . a . prospective. . multicentre. . cohort. . study. .. Serrano-Villar S, et al. . Lancet. HIV 2020; 7: e565-73. Juan E. Losa. With Emergence of Comorbidities. Roger J. . Bedimo. , MD. Professor of Medicine. University of Texas Southwestern Medical Center. Dallas, TX. Learning Objectives. On completion of this presentation, learners will be able to:. Constance A. Benson, MD. Professor of Medicine and Global Public Health. University of California San Diego. La Jolla, California. Goals for the Workshop. To describe the potential benefits of long-acting antiretroviral drugs (ARVs) for treatment and prevention of HIV infection.